Not all cancer cells that detach from the primary tumor and embark on a journey to another organ colonize it. To establish themselves, cells need specific conditions. Scientists at the Federal Institute of Technology Zurich (ETH Zurich) explored this hypothesis in the liver and identified a protein involved in metastatic transformation. Blocking it prevented liver metastasis. Their findings may have applications in other organs and various types of cancers.
With $50 million in hand from Flagship Pioneering, Abiologics Inc. is pairing generative artificial intelligence with high-throughput chemical protein synthesis to attack oncology and immunology indications with Synteins, synthetic proteins that represent a new class of programmable medicines. Avak Kahvejian, co-founder and CEO of Abiologics and general partner at Flagship, told BioWorld that Abiologics stands “at the precipice of a completely new modality.”
Genechem Inc. has created conjugates comprising gemcitabine covalently linked to sialyllactose through a linker and reported to be useful for the treatment of cancer.
Medipol Ueniversitesi Zonguldak Buelent Ecevit University has patented new specific arylidene barbiturate derivatives reported to be useful for the treatment of cancer.
Shanghai Wennai Pharmaceutical Technology Co. Ltd. has described new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of breast and prostate cancer.
Vidac Pharma Holdings plc has released the results of preclinical studies with VDA-1275 in multiple mouse cancer and human cellular organoid models of solid tumors.
Dren Bio Inc. has entered into a strategic collaboration with Novartis Pharma AG which will focus on the discovery and development of therapeutic bispecific antibodies for cancer leveraging Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform.
RSS
